Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00020618 · ClinicalTrials.gov registry record · Phase 2
Inhaled Morphine Compared With Morphine By Mouth in Treating Cancer Patients With Breakthrough Pain
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00020618: Completed Phase 2 study, sponsored by Dana-Farber Cancer Institute.
NCT00020618 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00020618, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Morphine that is inhaled may be more rapidly absorbed than morphine that is given by mouth. It is not yet known if inhaled morphine is more effective than morphine given by mouth in relieving breakthrough pain. PURPOSE: Randomized phase II trial to compare the effectiveness of inhaled morphine with that of morphine given by mouth in treating cancer patients who have breakthrough pain.
Interventions
- PROCEDURE quality-of-life assessment
- DRUG morphine sulfate
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-03 |
| Est. Completion | 2004-02 |
| Phase | Phase 2 |
What the finished NCT00020618 record still lists
NCT00020618 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which quality-of-life assessment is the first listed.
NCT00020618 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00020618 about?
NCT00020618 is a clinical study titled "Inhaled Morphine Compared With Morphine By Mouth in Treating Cancer Patients With Breakthrough Pain". RATIONALE: Morphine that is inhaled may be more rapidly absorbed than morphine that is given by mouth. It is not yet known if inhaled morphine is more effective than morphine given by mouth in relieving breakthrough pain. PURPOSE: Randomized phase II trial to compare the effectiveness of inhaled mo...
What is the current status of trial NCT00020618?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-03. Estimated completion is 2004-02.
What interventions are being tested in trial NCT00020618?
The interventions under investigation include: quality-of-life assessment (PROCEDURE), morphine sulfate (DRUG).
Who is sponsoring clinical trial NCT00020618?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia